Potenzial nach massiven Kurssturz Balchem (905650)

A Downtrend for Balchem (NASDAQ:BCPC) on January 23rd, 2012 at $38.73. In approximately 2 months, Balchem has returned 22.67% as of today's recent price of $29.95.

Balchem share prices have moved between a 52-week high of $47.23 and a 52-week low of $26.56 and are now trading 13% above that low price at $29.95 per share. Over the last five market days, the 200-day moving average (MA) has gone down 0.4% while the 50-day MA has declined 2.1%.

Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. The Company micro-encapsulates performance ingredients, and also repackages and markets specialty gases. Balchem sells its products through its own sales force, independent distributors, and sales agents.

http://www.balchem.com/news/balchem-corporation-announces-fourth-quarter-2011-results

So schlecht schauen die Zahlen auch wieder nicht aus

aber trotzdem sehr interessant

Rosenheim (aktiencheck.de AG) - Die Experten von "boerse.de-Aktienbrief"  nutzen den Aufwärtstrendwechsel bei der Aktie von Balchem  (<US0576652004>/ <US0576652004>) zum Einstieg. Laut aktuellem Forbes-Ranking sei dieses US-Spezialchemieunternehmen die  Nummer 29 unter "Americas best Small Companies". Schwerpunkte seien  Nahrungsergänzungsmittel, Zusatzstoffe für die Pharmaindustrie,  Tierfutter sowie medizintechnische Spezialerzeugnisse. Damit seien im  dritten Quartal abermals Rekordergebnisse verbucht worden, wobei die  Umsätze um 16% auf 74 Mio. USD gestiegen seien, während der Gewinn (11  Mio. USD) sogar um 27% nach oben geschnellt sei. Die Aktie glänze mit  einem mustergültigen Kursverlauf von links unten nach rechts oben, der  sich in hervorragenden Performance-Kennzahlen niederschlage. Seit 2001  sei Balchem mit einer hohen Gewinn-Konstanz im Schnitt 24% p.a.  aufgesattelt, wobei die Verlust-Ratio von 2,09 unterdurchschnittlich  ausfalle. Nach dem August-Rücksetzer gelang jetzt der erneute Aufwärtstrendwechsel  bei der Balchem-Aktie, den die Experten von "boerse.de-Aktienbrief" zum  zweiten Einstieg nutzen. Damit würden sie sich 12% Crash-Rabatt  gegenüber dem Juli-All-Time-High sichern, und bis 2016 errechne sich  eine Gewinn-Perspektive von 170%. (Ausgabe 253 vom 16.11.2011)  (18.11.2011/ac/a/a)

http://www.fool.com/investing/general/2012/05/03/...timates-on-e.aspx

Balchem ( Nasdaq: BCPC     ) reported earnings yesterday. Here are the numbers you need to

... (automatisch gekürzt) ...

http://www.fool.com/investing/general/2012/05/03/...timates-on-e.aspx

The 10-second takeaway
For the quarter ended June 30 (Q2), Balchem beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.

Gross margins dropped, operating margins were steady, net margins dropped.

Revenue details
Balchem reported revenue of $79.0  million. The three analysts polled by S&P Capital IQ predicted  revenue of $76.0 million on the same basis. GAAP reported sales were  5.8% higher than the prior-year quarter's $74.7 million.

Balchem Corporation Announces Third Quarter 2012 Results

www.balchem.com/news/...n-announces-third-quarter-2012-results

www.boerse.de/top-news/...em-188Prozent-Kurspotenzial-/7456255

schaut's auch gut aus

www.balchem.com/news/...n-Announces-First-Quarter-2014-Results

This release contains forward-looking statements, which reflect Balchem's expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Balchem's expectations, including risks and factors identified in Balchem's annual report on Form 10-K for the year ended December 31, 2013. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.


finance.yahoo.com/news/...on-announces-dividend-200000807.html

balchem.com/investor-relations

balchem.com/news/...lchem-announces-first-quarter-2015-results

de.4-traders.com/BALCHEM-CORPORATION-39847/fundamentals/

balchem.com/sites/default/files/...esentation%20May%202015.pdf

seekingalpha.com/article/...ity-in-this-world-class-compounder

hat in diesem Jahr fast nur die Seitwärtsbewegung ausgeführt und hat in den
letzten Tagen vermutlich den Weg nach Norden gewählt.
Die Aktie habe ich am 27.5.2014 für 41,34€ gekauft, heute steht sie 57,6€.
Wie ich gelesen habe, gilt sie als unterbewertet. Der Kurs scheint in Bewegung zu
kommen, und zwar in die richtige Richtung nach Norden und hat ein Hoch gebildet,
zudem kommt im Dez. die Div.-Zahlung. Die Höhe der bisherigen Zahlungen scheint
stetig nach oben zu gehen und dies kann ich als stabil bezeichnen. Ich glaube, eine
gute Kaufgelegenheit mit Signal.

finance.yahoo.com/news/...albion-international-180810470.html

Balchem Corporation Acquires Albion International, Inc.

NEW HAMPTON, N.Y., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Balchem Corporation (BCPC) today announced that it acquired Albion International, Inc., a privately held manufacturer of mineral amino acid chelates, specialized mineral salts and mineral complexes, headquartered in Clearfield, Utah for a purchase price of $111.5 million in cash. Albion’s 2015 revenues were approximately $53.5 million. The acquisition purchase price reflects a multiple of approximately 10.7 times 2015 EBITDA, excluding any synergies. The transaction consideration is subject to certain adjustments as provided in the definitive agreement. The purchase price will be financed through the Company’s existing revolving credit facility and cash on hand.  The transaction is expected to be immediately accretive to Balchem’s earnings per share.




Albion has been a world leader and innovator in the manufacture of superior organic mineral compounds for sixty years.  With over 100 patents, Albion leverages scientific expertise in the areas of both human and plant nutrition. Albion’s products are renowned in the supplement industry for technologically advanced, unparalleled bioavailability.

With this acquisition, Balchem continues to expand its science based human health and wellness solutions.  Already the global leader in the essential nutrient, choline, Balchem will immediately expand the combined company's product offerings in the nutritional ingredient market by adding Albion’s premier branded innovative chelated minerals to its portfolio.  The combined company will also benefit from a broader geographic footprint and an even stronger position as a technological leader in spray-drying and ingredient delivery solutions.

“We are very excited to add Albion’s deep scientific expertise, broad patent portfolio, and premium branded products to our company.  This acquisition creates a broader nutritional platform for Balchem that will help our customers improve their nutritional and wellness solutions,” said Ted Harris, President and CEO of Balchem.

About Balchem
Balchem Corporation consists of four business segments:  SensoryEffects; Animal Nutrition and Health; Specialty Products; and Industrial Products.  The SensoryEffects segment provides customized food and beverage ingredient systems and proprietary microencapsulation solutions to a variety of applications in the human food, pharmaceutical and nutrition marketplaces. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and the Industrial Products segment, provides certain derivative products into industrial applications, predominately as a component for hydraulic fracturing of shale natural gas wells.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Balchem or SensoryEffects and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations and risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2014. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date, except as required by law.


Contact:


Balchem Contact:
Suzanne Hart, Investor Relations
Telephone:  845-326-5600
E-mail: bcpc-ir@balchem.com

seekingalpha.com/article/...5-results-earnings-call-transcript


Balchem Corporation Reports Record Adjusted Earnings Per Share of $2.51 for Full Year 2015; Fourth Quarter Adjusted Earnings Per Share of $0.66



seekingalpha.com/pr/...gs-per-share-2_51-full-year-2015-fourth

finance.yahoo.com/news/...ports-adjusted-ebitda-130000120.html
.
NEW HAMPTON, N.Y., May 10, 2016 (GLOBE NEWSWIRE) -- Balchem Corporation (BCPC) today reported for the first quarter 2016 adjusted EBITDA(a) of $35.5 million, compared to $36.1 million in the prior year quarter and $33.7 million sequentially from the fourth quarter 2015. Adjusted EBITDA margin expanded to 26.2% from 24.9% and 25.4% in the prior year quarter and fourth quarter 2015, respectively, and this was a significant contributor to these results in a challenging oil & gas and dairy market environment.


First Quarter 2016 Financial Highlights:
•Net sales of $135.1 million, a decrease of 6.7% compared to the first quarter of 2015, with the most significant driver of this decline being a $13.6 million reduction in sales in Industrial Products.
•Without the impact of Albion, record first quarter earnings for our Human Nutrition & Health (formerly SensoryEffects)(b) segment and record first quarter sales and record first quarter earnings for our Specialty Products(c) segment.
•Adjusted EBITDA margin improved to 26.2% versus 24.9% in the first quarter 2015 and 25.4% sequentially from the fourth quarter 2015 principally due to improved product mix and lower raw material costs.
•Adjusted earnings per share(a) of $0.58 decreased $0.04 or 6.5% from the prior year.
•Record first quarter cash flows from operations generated of $29.3 million.

www.zacks.com/research/get_news.php?id=udt4ejivwb

finance.yahoo.com/news/blachem-posts-4q-profit-132332147.html

seekingalpha.com/article/...chem-intact-long-term-growth-story

www.4-traders.com/...5-Million-and-First-Quarter-Adj-24352771/

www.4-traders.com/...e-beating-Walls-Streets-expecta-24895966/

www.4-traders.com/...h-Record-Third-Quarter-Net-Earn-25454884/

www.4-traders.com/...ith-Record-Net-Earnings-of-42-0-26067026/

www.4-traders.com/...illion-Record-First-Quarter-Net-26514877/

www.marketscreener.com/...chem-3Q-Earnings-Snapshot-27555451/

www.marketscreener.com/...d-Quarter-Net-Earnings-of-27554610/

www.marketscreener.com/...es-of-163-5-million-Fourt-28085287/

02/28/2019 | 07:03am EST
Fourth quarter net sales of $163.5 million, growth of 2.7%, compared to prior year. Full year 2018 sales of $643.7 million, an increase of 8.2% from the prior year, with year over year sales growth in all four of our segments.
Fourth quarter GAAP EPS of $0.63, and adjusted EPS(a) of $0.77, an increase in adjusted EPS(a) of 13.2% compared to prior year. Full year GAAP EPS of $2.42, and adjusted EPS(a) of $3.01, an increase in adjusted EPS(a) of 19.0% from the prior year.
Fourth quarter cash flow from operations of $39.5 million and free cash flow(a) of $33.6 million, up 57.6% compared to prior year. Full year cash flow from operations of $118.7 million and free cash flow(a) of $99.5 million, up 19.8% compared to prior year.

www.globenewswire.com/news-release/2019/05/...EPS-of-0-73.html

www.marketscreener.com/...chem-3Q-Earnings-Snapshot-29517948/

www.balchem.com/wp-content/uploads/2020/...elease-Q4-2019.pdf

www.balchem.com/investor-relations/

Current Financials: Updated: February 21, 2020

• Fourth quarter net sales of $166.5 million, an increase of $3.0 million, or 1.8%, compared to the prior year quarter.
• Year over year quarterly sales growth in three of the four segments, with all-time record sales in Human Nutrition and Health and Animal Nutrition and Health, and record fourth quarter sales in Specialty Products.
• Fourth quarter GAAP net earnings of $20.4 million were slightly higher than the prior year. These net earnings resulted in GAAP earnings per share of $0.63.
• Quarterly adjusted net earnings of $28.4 million increased $3.3 million or 12.9% from the prior year, resulting in adjusted earnings per share of $0.88.
• Fourth quarter adjusted EBITDA was $40.0 million, an increase of $0.4 million, or 1.0%, from the prior year.
• Quarterly cash flows from operations were $33.0 million for the fourth quarter 2019 with quarterly free cash flow of $26.3 million.



Full Year 2019 Financial Highlights
• Full year net sales of $643.7 million were slightly higher than the prior year.
• Year over year sales growth in three of the four segments, with all-time record sales in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, offset by reduced sales in Industrial Products.
• Full year GAAP net earnings were $79.7 million, an increase of $1.1 million, or 1.4% from the prior year. These net earnings resulted in GAAP earnings per share of $2.45.
• Full year adjusted net earnings of $103.7 million increased $5.9 million or 6.1% from the prior year, resulting in adjusted earnings per share of $3.19.
• Full year adjusted EBITDA was $160.0 million, an increase of $0.7 million, or 0.5%, from the prior year.
• Full year cash flows from operations were $124.5 million for 2019 with full year free cash flow of $96.1 million.

www.marketscreener.com/...chem-2Q-Earnings-Snapshot-31030373/

www.marketscreener.com/...Results-of-Operations-All-31032722/

www.marketscreener.com/quote/stock/...ings-Snapshot-32481161/

seekingalpha.com/article/...&utm_source=twitter_automated

Blachem: Q2 Earnings Snapshot
07/30/2021 | 12:30pm BST

NEW HAMPTON, N.Y. (AP) _ Balchem Corp. (BCPC) on Friday reported second-quarter profit of $22.7 million.

On a per-share basis, the New Hampton, New York-based company said it had net income of 70 cents. Earnings, adjusted for one-time gains and costs, were 93 cents per share.

The chemical company posted revenue of $202.4 million in the period.

Blachem shares have increased 16% since the beginning of the year. The stock has increased 35% in the last 12 months.

This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCPC at www.zacks.com/ap/BCPC

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

www.marketscreener.com/quote/stock/...ings-Snapshot-36017411/

www.marketscreener.com/quote/stock/...perations-All-36023486/

de.marketscreener.com/kurs/aktie/...msatzsteigerung-42206953/

Balchem's Q3 bereinigtes Ergebnis, Umsatzsteigerung
04.11.2022 | 12:36

(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das 3. Quartal einen bereinigten Gewinn von $1,00 je verwässerter Aktie, nach $0,92 im Vorjahr.

Einer von zwei von Capital IQ befragten Analysten hatte $1,03 erwartet.

Der Nettoumsatz für das Quartal, das am 30. September endete, betrug 244,3 Mio. $, verglichen mit 197,9 Mio. $ im Vorjahr.

Drei von Capital IQ befragte Analysten hatten 239,6 Millionen Dollar erwartet.
de.marketscreener.com/kurs/aktie/...msatzsteigerung-42206953/

de.marketscreener.com/kurs/aktie/...s-Umsatzanstieg-43076829/

(MT Newswires) -- Balchem (BCPC) hat am Freitag für das vierte Quartal einen bereinigten Gewinn von $0,94 je verwässerter Aktie ausgewiesen, gegenüber $0,85 je Aktie im Vorjahr.

Ein einziger von Capital IQ befragter Analyst erwartete ein bereinigtes EPS von $0,91.

Der Nettoumsatz für das am 31. Dezember beendete Quartal belief sich auf 232,5 Mio. $, verglichen mit 213,1 Mio. $ vor einem Jahr. Drei von Capital IQ befragte Analysten hatten 241,5 Millionen Dollar erwartet.

de.marketscreener.com/kurs/aktie/...t-Umsatz-steigt-43679893/

Balchem's Q1 bereinigter Gewinn sinkt, Umsatz steigt
28.04.2023 | 14:26

(MT Newswires) -- Balchem (BCPC) hat am Freitag für das erste Quartal einen bereinigten Gewinn von $0,94 pro verwässerter Aktie ausgewiesen, gegenüber $1,03 pro Aktie im Vorjahr.

Ein von Capital IQ befragter Analyst erwartete ein bereinigtes EPS von $0,82.

Der Nettoumsatz für das am 31. März beendete Quartal lag bei 232,5 Mio. $, gegenüber 228,9 Mio. $ im Vorjahr. Drei von Capital IQ befragte Analysten hatten $233,5 Millionen erwartet.

de.marketscreener.com/kurs/aktie/...-Umsatzruckgang-44453209/

Balchem's Q2 bereinigtes Ergebnis, Umsatzrückgang
Heute um 14:11

(MT Newswires) -- Balchem (BCPC) hat am Freitag für das 2. Quartal einen bereinigten Gewinn von $1,06 je verwässerter Aktie ausgewiesen, gegenüber $1,07 im Vorjahr.
Ein von Capital IQ befragter Analyst hatte 0,93 $ pro Aktie erwartet.

Der Nettoumsatz für das Quartal, das am 30. Juni endete, lag bei $ 231,3 Millionen, gegenüber $ 236,7 Millionen im Vorjahr.

Drei von Capital IQ befragte Analysten hatten 244,9 Millionen Dollar erwartet.

de.marketscreener.com/kurs/aktie/...ttoumsatz-sinkt-45172656/

Balchem Q3 bereinigter Gewinn steigt, Nettoumsatz sinkt
Am 27. Oktober 2023 um 14:53 Uhr

(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das 3. Quartal einen bereinigten Nettogewinn von $1,04 je verwässerter Aktie, gegenüber $1,00 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,97 erwartet.

Der Nettoumsatz für das Quartal, das am 30. September endete, lag bei 229,9 Mio. $, gegenüber 244,3 Mio. $ im Vorjahresquartal.

Drei von Capital IQ befragte Analysten hatten $237,1 Millionen erwartet.

Balchem's Q4 bereinigtes Ergebnis steigt, Nettoumsatz sinkt
Am 16. Februar 2024 um 13:53 Uhr

(MT Newswires) -- Balchem (BCPC) meldete am Freitag für das vierte Quartal einen bereinigten Gewinn von $0,95 pro verwässerter Aktie, gegenüber $0,94 im Vorjahr.
Zwei von Capital IQ befragte Analysten hatten $0,93 erwartet.

Der Nettoumsatz für das Quartal, das am 31. Dezember endete, lag bei $228,7 Millionen, verglichen mit $232,5 Millionen im Jahr zuvor.

Die von Capital IQ befragten Analysten hatten $234,7 Millionen erwartet.